Year archive

Swedish Orphan Biovitrum — 2013 filings

All 79 regulatory filings released by Swedish Orphan Biovitrum (SOBI) in 2013, sourced directly from the official regulator.

79 Filings

2013 Period

2013 filings (79)

Filing	Released	Lang
Sobi drar tillfälligt tillbaka sin ansökan om en flytande formulering av Orfadin® i USA Legal Proceedings Report	2013-12-27	Swedish
Sobi to temporarily withdraw New Drug Application for Orfadin® oral suspension in the US Regulatory Filings	2013-12-27	English
Sobi övertar ansvaret för Orfadin i USA, Kanada och Latinamerika Regulatory Filings	2013-12-20	Swedish
Sobi to take direct responsibility for Orfadin in the US, Canada and Latin America Regulatory Filings	2013-12-20	English
Swedish Orphan Biovitrum AB (publ): New phase 3 data confirm long-lasting characteristics of rFIXFc and rFVIIIFc across multiple haemophilia populations Earnings Release FY 2013	2013-12-09	English
Swedish Orphan Biovitrum AB (publ): Ny fas-3-data bekräftar förlängd halveringstid för hemofiliproduktkandidater över flera patientgrupper Investor Presentation	2013-12-09	Swedish
Förebyggande injektioner av Alprolix(TM) motverkar effektivt blödningar hos patienter med hemofili B visar ny data som publiceras i den vetenskapliga tidsskriften New England Journal of Medicine Earnings Release FY 2013	2013-12-05	Swedish
The New England Journal of Medicine publishes pivotal data demonstrating prophylactic infusions of Alprolix(TM) effectively controlled bleeding in haemophilia B patients Earnings Release FY 2013	2013-12-05	English
Sobis partner Biogen Idec avser att presentera fas-3 data om förlängd halveringstid av hemofiliproduktkandidater i barn vid det årliga ASH-mötet Regulatory Filings	2013-12-03	Swedish
Sobi's partner Biogen Idec to present phase 3 data on prolonged half-life of Haemophilia candidates in young children at annual ASH meeting Regulatory Filings	2013-12-03	English
Sobi's partner Biogen Idec receives notification from FDA of PDUFA date extension for ALPROLIX(TM) Regulatory Filings	2013-12-02	English
Sobis partner Biogen Idec har fått besked av FDA om förskjuten tidslinje för ALPROLIX(TM) i USA Regulatory Filings	2013-12-02	Swedish
New number of shares and votes in Swedish Orphan Biovitrum AB (publ) Share Issue/Capital Change	2013-11-29	English
Ändring av antalet aktier och röster i Swedish Orphan Biovitrum AB (publ) Declaration of Voting Results & Voting Rights Announcements	2013-11-29	Swedish
Sobi: Europeiska Kommissionen godkänner Kineret® för behandling av CAPS Regulatory Filings	2013-11-20	Swedish
Sobi receives approval for Kineret® for treatment of rare disease CAPS Regulatory Filings	2013-11-20	English
Sobi's partner Biogen Idec expects mid-2014 US launch of ELOCTATE® Regulatory Filings	2013-11-12	English
Sobis partner Biogen Idec räknar med lanseringen av ELOCTATE® i mitten av 2014 Regulatory Filings	2013-11-12	Swedish
Sobi hosts Capital Market Day event - announces phase I Complement Inhibitor program Investor Presentation	2013-11-05	English
Sobi tillkännager ny klinisk fas I prövning på kapitalmarknadsdag Investor Presentation	2013-11-05	Swedish
Interim / Quarterly Report 2013 Interim / Quarterly Report Q3 2013	2013-10-30	Swedish
Interim / Quarterly Report 2013 Interim / Quarterly Report Q3 2013	2013-10-30	English
Sobi publicerar resultaten för det tredje kvartalet 2013 Interim / Quarterly Report Q3 2013	2013-10-30	Swedish
Sobi publishes Report for the Third Quarter 2013 Interim / Quarterly Report Q3 2013	2013-10-30	English
Sobi lämnar in ansökan för en flytande formulering av Orfadin® till FDA Regulatory Filings	2013-10-29	Swedish
Sobi submits application for Orfadin® oral suspension to FDA Regulatory Filings	2013-10-29	English
Major Shareholding Notification 2013 Major Shareholding Notification	2013-10-10	English
Major Shareholding Notification 2013 Major Shareholding Notification	2013-10-09	English
New number of shares and votes in Swedish Orphan Biovitrum AB (publ) Declaration of Voting Results & Voting Rights Announcements	2013-10-01	English
Ändring av antalet aktier och röster i Swedish Orphan Biovitrum AB (publ) Declaration of Voting Results & Voting Rights Announcements	2013-10-01	Swedish
Sobi receives positive CHMP opinion for Kineret® for treatment of rare disease CAPS Regulatory Filings	2013-09-23	English
CHMP rekommenderar att Sobis Kineret godkänns för behandling av CAPS Regulatory Filings	2013-09-23	Swedish
The Board of Directors exercises authorization for repurchase of shares for the purpose of securing the company's commitments under the incentive program Transaction in Own Shares	2013-09-13	English
Styrelsen utnyttjar återköpsbemyndigande för säkerställande av bolagets åtaganden enligt incitamentsprogram Transaction in Own Shares	2013-09-13	Swedish
Major Shareholding Notification 2013 Major Shareholding Notification	2013-09-12	English
Sobi acquires full rights for Kineret® and additional clinical data for Kepivance® from Amgen Regulatory Filings	2013-09-09	English
Sobi förvärvar samtliga rättigheter för Kineret® samt kliniska data för Kepivance® från Amgen M&A Activity	2013-09-09	Swedish
Sobi appoints Dennis Schmidt Pedersen as Senior Vice President Human Resources Board/Management Information	2013-09-03	English
Sobi utser Dennis Schmidt Pedersen till personaldirektör Board/Management Information	2013-09-03	Swedish
Sobi submits application for Orfadin® oral suspension to EMA Regulatory Filings	2013-08-22	English
Sobi lämnar in ansökan för en flytande formulering av Orfadin® till EMA Regulatory Filings	2013-08-22	Swedish
Interim / Quarterly Report 2013 Interim / Quarterly Report Q2 2013	2013-07-18	Swedish
Interim / Quarterly Report 2013 Interim / Quarterly Report Q2 2013	2013-07-18	English
Sobi publishes Report for the Second Quarter 2013 Interim / Quarterly Report Q2 2013	2013-07-18	English
Sobi publicerar resultaten för det andra kvartalet 2013 Interim / Quarterly Report Q2 2013	2013-07-18	Swedish
Auxilium Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (publ) enter a collaboration agreement for XIAPEX® in 71 Eurasian and African countries Regulatory Filings	2013-07-16	English
Auxilium Pharmaceuticals, Inc. och Swedish Orphan Biovitrum ab (publ) ingår samarbetsavtal gällande XIAPEX® i 71 europeiska, asiatiska och afrikanska länder Regulatory Filings	2013-07-16	Swedish
Biogen Idec och Sobi presenterar ny data från fas 3-studien för sin långverkande hemofililäkemedelskandidat ELOCTATE(TM) Investor Presentation	2013-07-04	Swedish
Biogen Idec and Sobi Present New Data from the Phase 3 Study of their Long-Lasting Haemophilia Factor Candidate ELOCTATE(TM) Regulatory Filings	2013-07-04	English
Biogen Idec och Sobi presenterar ny data från fas 3-studien för sin långverkande hemofililäkemedelskandidat ALPROLIX (TM) Earnings Release FY 2013	2013-07-02	Swedish
Biogen Idec and Sobi Present New Data from the Phase 3 Study of their Long-Lasting Haemophilia Factor Candidate ALPROLIX (TM) Regulatory Filings	2013-07-02	English
Major Shareholding Notification 2013 Major Shareholding Notification	2013-06-17	English
Sobi får FDA-godkännande att tillverka läkemedelssubstansen för Kineret® med partnern Boehringer Ingelheim Regulatory Filings	2013-06-11	Swedish
Sobi gets FDA approval to manufacture substance for Kineret® with partner Boehringer Ingelheim Regulatory Filings	2013-06-11	English
Sobi utnämner Mats-Olof Wallin till Finansdirektör Board/Management Information	2013-05-17	Swedish
Sobi appoints Mats-Olof Wallin as permanent Chief Financial Officer Board/Management Information	2013-05-17	English
Kommuniké från Sobis årsstämma AGM Information	2013-04-26	Swedish
Resolutions from Sobi's Annual General Meeting (AGM) AGM Information	2013-04-26	English
Interim / Quarterly Report 2013 Interim / Quarterly Report Q1 2013	2013-04-26	Swedish
Interim / Quarterly Report 2013 Interim / Quarterly Report Q1 2013	2013-04-26	English
Sobi appoints Mats-Olof Wallin as interim Chief Financial Officer Board/Management Information	2013-04-08	English
Sobi utnämner Mats-Olof Wallin till tillförordnad Finansdirektör Board/Management Information	2013-04-08	Swedish
Sobi publishes Annual Report Report Publication Announcement	2013-04-05	English
Sobis årsredovisning publicerad Report Publication Announcement	2013-04-05	Swedish
Annual Report 2012 Annual Report FY 2012	2013-04-05	Swedish
Annual Report 2012 Annual Report FY 2012	2013-04-05	English
EXELIXIS VÄLJER SWEDISH ORPHAN BIOVITRUM AB SOM EUROPEISK DISTRIBUTÖR FÖR COMETRIQ (TM) FÖR MEDULLÄR TYREOIDEACANCER Regulatory Filings	2013-02-22	Swedish
EXELIXIS SELECTS SWEDISH ORPHAN BIOVITRUM AB AS COMETRIQ (TM) EUROPEAN DISTRIBUTOR FOR MEDULLARY THYROID CANCER Regulatory Filings	2013-02-22	English
Sobis ytterligare emission om 200 Mkr under nuvarande obligationslån fulltecknad Capital/Financing Update	2013-02-21	Swedish
Sobi's additional issuance of SEK 200 million under current bond loan fully subscribed Capital/Financing Update	2013-02-21	English
Interim / Quarterly Report 2012 Interim / Quarterly Report Q4 2012	2013-02-21	Swedish
Interim / Quarterly Report 2012 Interim / Quarterly Report Q4 2012	2013-02-21	English
Sobi och Savient Pharmaceuticals tillkännager marknadsföringsavtal för Kineret® (anakinra) i USA Regulatory Filings	2013-02-19	Swedish
Sobi and Savient Pharmaceuticals Announce Co-Promotion Agreement for Kineret® (anakinra) in the U.S. M&A Activity	2013-02-19	English
Sobi erhåller distributionsrättigheter för Megace®, Monopril®, Cefzil® och Duricef® från PharmaSwiss Regulatory Filings	2013-02-13	Swedish
Sobi gains distribution rights for Megace®, Monopril®, Cefzil® and Duricef® from PharmaSwiss Regulatory Filings	2013-02-13	English
NYA FAS III-RESULTAT STÖDER LÅNGVERKANDE SKYDD MOT BLÖDNING FÖR PATIENTER MED HEMOFILI A OCH B Earnings Release FY 2013	2013-02-08	Swedish
NEW PHASE 3 DATA REINFORCE LONG-LASTING PROTECTION FROM BLEEDING FOR PATIENTS WITH HEMOPHILIA A AND B Earnings Release FY 2013	2013-02-08	English
Major Shareholding Notification 2013 Major Shareholding Notification	2013-01-18	English

Filings by year

2026 16 filings
2025 35 filings
2024 29 filings
2023 48 filings
2022 23 filings
2021 31 filings
2020 44 filings
2019 38 filings
2018 31 filings
2017 34 filings
2016 47 filings
2015 52 filings
2014 58 filings
2013 79 filings
2012 65 filings
2011 51 filings
2010 78 filings
2009 69 filings
2008 51 filings
2007 10 filings